12 Health Care Stocks Moving In Thursday's Pre-Market Session

Benzinga · 04/17 12:09
Gainers
- Channel Therapeutics (AMEX:CHRO) stock increased by 86.5% to $2.34 during Thursday's pre-market session. The market value of their outstanding shares is at $14.1 million.
- Sharps Technology (NASDAQ:STSS) stock rose 34.33% to $0.04.
- InnovAge Holding (NASDAQ:INNV) stock increased by 19.71% to $3.4. The market value of their outstanding shares is at $459.8 million.
- Quoin Pharmaceuticals (NASDAQ:QNRX) stock increased by 19.35% to $7.16. The market value of their outstanding shares is at $147.4 million.
- Sunshine Biopharma (NASDAQ:SBFM) shares rose 14.75% to $1.4. The market value of their outstanding shares is at $5.0 million.
- China SXT Pharmaceuticals (NASDAQ:SXTC) shares rose 14.25% to $1.13. The company's market cap stands at $15.5 million.
Losers
- Forian (NASDAQ:FORA) shares fell 36.0% to $1.26 during Thursday's pre-market session. The market value of their outstanding shares is at $39.3 million.
- TNF Pharmaceuticals (NASDAQ:TNFA) shares decreased by 23.9% to $0.19. As per the news, the Q4 earnings report came out 4 days ago.
- Sophia Genetics (NASDAQ:SOPH) stock declined by 19.58% to $2.26. The company's market cap stands at $150.1 million.
- UnitedHealth Group (NYSE:UNH) stock declined by 19.33% to $472.0. The company's market cap stands at $431.7 billion. As per the press release, Q1 earnings came out today.
- Tourmaline Bio (NASDAQ:TRML) shares declined by 15.98% to $12.2. The company's market cap stands at $313.3 million.
- enVVeno Medical (NASDAQ:NVNO) shares declined by 15.13% to $2.02. The company's market cap stands at $35.4 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.